What to Know About OrbiMed's $39 Million Enliven Therapeutics Stock Sale Amid a 130% Rally
Focused on cancer therapies, this Boulder-based biotech reported significant insider selling amid a year of sharp share price gains.
Overview
On June 22, 2026, Orbimed Advisors, a 10% Owner of Enliven Therapeutics, Inc. (NASDAQ:ELVN), disclosed the indirect sale of 860,123 shares for a total transaction value of approximately $39.0 million, as reported in the SEC Form 4 filing.
Transaction value based on SEC Form 4 weighted average purchase price ($45.36); post-transaction value based on June 22, 2026 market close.
Details
* 1-year performance calculated using June 22nd, 2026 as the reference date.
Source
Originally published at www.fool.com.
Related Articles
Disclaimer: This article is for informational purposes only and does not constitute investment advice. Data may be delayed up to 15 minutes. Past performance is not indicative of future results. Consult a licensed financial advisor before making investment decisions.